In our previous paper, we showed that intraperitoneal administration of the DAGLα inhibitor LEI‐106 induced headache‐like symptoms, including cutaneous allodynia at the cephalic site, and spontaneous pain behaviour, like head‐pressing and photophobia (Levine et al., 2021). Here, DAGLA is linked to Headache.